• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

将重点从药物基因组学转向治疗诊断学。

Shifting emphasis from pharmacogenomics to theragnostics.

作者信息

Ozdemir Vural, Williams-Jones Bryn, Glatt Stephen J, Tsuang Ming T, Lohr James B, Reist Christopher

机构信息

Biomarker and Clinical Pharmacology Unit, VA Long Beach Healthcare System, Southern California Institute for Research and Education, University of California, Irvine, CA, USA.

出版信息

Nat Biotechnol. 2006 Aug;24(8):942-6. doi: 10.1038/nbt0806-942.

DOI:10.1038/nbt0806-942
PMID:16900136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7096916/
Abstract

What will be the role of theragnostic patents in upstream and downstream biomarker research?

摘要

诊疗一体化专利在上游和下游生物标志物研究中将发挥什么作用？

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78c/7096916/e50d60638878/41587_2006_Article_BFnbt0806942_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78c/7096916/e50d60638878/41587_2006_Article_BFnbt0806942_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f78c/7096916/e50d60638878/41587_2006_Article_BFnbt0806942_Fig1_HTML.jpg

相似文献

1
Shifting emphasis from pharmacogenomics to theragnostics.将重点从药物基因组学转向治疗诊断学。
Nat Biotechnol. 2006 Aug;24(8):942-6. doi: 10.1038/nbt0806-942.
2
Pharmacogenetics and pharmacogenomics in the discovery and development of medicines.药物遗传学与药物基因组学在药物发现与开发中的应用
Novartis Found Symp. 2000;229:63-6; discussion 66-70. doi: 10.1002/047084664x.ch9.
3
Challenges and opportunities in pharmacogenomics and therapeutics.药物基因组学与治疗学中的挑战与机遇。
J Manag Care Pharm. 2007 Sep;13(7):607-8. doi: 10.18553/jmcp.2007.13.7.607.
4
"Pharmacogenomics: achievements, challenges and prospects, for patients, pharmaceutical industries and healthcare systems".《药物基因组学：对患者、制药行业和医疗保健系统而言的成就、挑战与前景》
Curr Pharm Des. 2010;16(20):2182-3. doi: 10.2174/138161210791792840.
5
Pharmacogenomics: the promise of personalized medicine.药物基因组学：个性化医疗的前景。
Environ Health Perspect. 2003 Aug;111(11):A581-9. doi: 10.1289/ehp.111-1241640.
6
Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy.小鼠药物基因组学：利用小鼠了解药物治疗的遗传学
Pharmacogenomics. 2002 Nov;3(6):781-90. doi: 10.1517/14622416.3.6.781.
7
Personalized pharmacotherapy: genotypes, biomarkers, and beyond.个性化药物治疗：基因分型、生物标志物及其他
Clin Pharmacol Ther. 2009 Feb;85(2):142. doi: 10.1038/clpt.2008.228. Epub 2008 Nov 12.
8
Pharmacogenetics, pharmacogenomics and airway disease.药物遗传学、药物基因组学与气道疾病
Respir Res. 2002;3(1):10. doi: 10.1186/rr159. Epub 2001 Nov 26.
9
Asthma pharmacogenomics.哮喘药物基因组学
Immunol Allergy Clin North Am. 2005 Nov;25(4):723-42. doi: 10.1016/j.iac.2005.09.004.
10
Structural pharmacogenomics: the answer to antimicrobial drug resistance?结构药物基因组学：对抗菌药物耐药性的答案？
Drug Discov Today. 2003 Feb 1;8(3):110-1. doi: 10.1016/s1359-6446(02)02591-6.

引用本文的文献

1
NIR-715 photodynamic therapy induces immunogenic cancer cell death by enhancing the endoplasmic reticulum stress response.近红外715光动力疗法通过增强内质网应激反应诱导免疫原性癌细胞死亡。
Cell Death Dis. 2024 Dec 18;15(12):890. doi: 10.1038/s41419-024-07283-4.
2
Impact of endocrine disrupting chemicals and pharmaceuticals on Sertoli cell development and functions.内分泌干扰化学物质和药物对支持细胞发育和功能的影响。
Front Endocrinol (Lausanne). 2023 Jan 30;14:1095894. doi: 10.3389/fendo.2023.1095894. eCollection 2023.
3
Stratifying non-small cell lung cancer patients using an inverse of the treatment decision rules: validation using electronic health records with application to an administrative database.

本文引用的文献

1
Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.非专利抗精神病药物的药物遗传学：重新审视迟发性运动障碍的风险与基本药物的可及性
Expert Opin Pharmacother. 2006 Feb;7(2):119-33. doi: 10.1517/14656566.7.2.119.
2
Decoding the research exemption.解读研究豁免
Nat Rev Genet. 2006 Feb;7(2):148-54. doi: 10.1038/nrg1766.
3
Policy conflicts: gene patents and health care in Canada.政策冲突：加拿大的基因专利与医疗保健
采用治疗决策规则的逆序对非小细胞肺癌患者进行分层：利用电子健康记录进行验证，并应用于管理型数据库。
BMC Med Inform Decis Mak. 2023 Jan 6;23(1):3. doi: 10.1186/s12911-022-02088-x.
4
Precision Medicine in Control of Visceral Leishmaniasis Caused by .精准医学控制. 引起的内脏利什曼病
Front Cell Infect Microbiol. 2021 Nov 9;11:707619. doi: 10.3389/fcimb.2021.707619. eCollection 2021.
5
Neurotheranostics as personalized medicines.神经治疗学作为个性化药物。
Adv Drug Deliv Rev. 2019 Aug;148:252-289. doi: 10.1016/j.addr.2018.10.011. Epub 2018 Oct 26.
6
A Transcriptomic Biomarker to Quantify Systemic Inflammation in Sepsis - A Prospective Multicenter Phase II Diagnostic Study.一种用于量化脓毒症全身炎症反应的转录组生物标志物——一项前瞻性多中心II期诊断研究。
EBioMedicine. 2016 Apr;6:114-125. doi: 10.1016/j.ebiom.2016.03.006. Epub 2016 Mar 8.
7
Inhibitory effect of genetically engineered mesenchymal stem cells with Apoptin on hepatoma cells in vitro and in vivo.携带凋亡素的基因工程间充质干细胞对肝癌细胞的体内外抑制作用
Mol Cell Biochem. 2016 May;416(1-2):193-203. doi: 10.1007/s11010-016-2707-0. Epub 2016 May 3.
8
Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.精神分裂症的生物标志物：聚焦于基于血液的诊断和治疗。
World J Psychiatry. 2016 Mar 22;6(1):102-17. doi: 10.5498/wjp.v6.i1.102.
9
Cell type-specific delivery of short interfering RNAs by dye-functionalised theranostic nanoparticles.通过染料功能化的诊疗纳米颗粒实现短干扰RNA的细胞类型特异性递送。
Nat Commun. 2014 Dec 3;5:5565. doi: 10.1038/ncomms6565.
10
Molecular pathology - the value of an integrative approach.分子病理学——综合方法的价值
Mol Oncol. 2014 Oct;8(7):1163-8. doi: 10.1016/j.molonc.2014.07.021. Epub 2014 Aug 12.
Community Genet. 2005;8(4):223-7. doi: 10.1159/000087959.
4
Knowledge commons or economic engine--what's a university for?知识共享之地还是经济引擎——大学何为？
J Med Ethics. 2005 May;31(5):249-50. doi: 10.1136/jme.2005.012278.
5
Excess in the pharmaceutical industry.制药行业的过度行为。
CMAJ. 2004 Dec 7;171(12):1451-3. doi: 10.1503/cmaj.1041594.
6
The myth of the biotech revolution.生物技术革命的神话。
Trends Biotechnol. 2004 Nov;22(11):564-9. doi: 10.1016/j.tibtech.2004.09.010.
7
Tailored medicine: whom will it fit? The ethics of patient and disease stratification.精准医疗：谁将从中受益？患者与疾病分层的伦理问题。
Bioethics. 2004 Aug;18(4):322-42. doi: 10.1111/j.1467-8519.2004.00400.x.
8
Social contract theory and just decision making: lessons from genetic testing for the BRCA mutations.社会契约理论与公正决策：BRCA 突变基因检测的启示
Kennedy Inst Ethics J. 2004 Jun;14(2):115-42. doi: 10.1353/ken.2004.0026.
9
Actor-network theory: a tool to support ethical analysis of commercial genetic testing.行动者网络理论：一种支持商业基因检测伦理分析的工具。
New Genet Soc. 2003 Dec;22(3):271-96. doi: 10.1080/1463677032000147225.
10
Surviving the blockbuster syndrome.挺过轰动一时的综合征。
Science. 2004 Mar 19;303(5665):1796-9. doi: 10.1126/science.303.5665.1796.